Potassium supplements during long-term thiazide therapy for essential hypertension.
Increasing doses of a slow-release potassium supplement were given to nine hypertensive patients previously treated for at least 18 months with bendrofluazide 10 mg daily. Serum potassium and total body potassium (TBK) were measured after 2 months on each dose. No significant increase in serum potassium or TBK occurred over a 6 month period of supplementation using doses commonly prescribed in clinical practice.
D000328:Adult; D001581:Benzothiadiazines; D004232:Diuretics; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000008:administration & dosage* / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects*
D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D011188:Potassium